---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-068543"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-22T00:21:36.623668+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "medium"
source: SEC EDGAR
---

# Invivyd launches discovery program for measles monoclonal antibody; candidate target by 2025

## Summary
- Multiple healthcare providers have requested a monoclonal antibody for measles treatment and post-exposure prophylaxis from Invivyd.
- Goal is to identify a preclinical measles mAb candidate in 2025; progress update expected by end of year.
- Over 20 million Americans are unvaccinated; U.S. at risk of losing functional elimination as vaccination rates decline.
- No approved therapies currently exist for measles; current options include high-dose Vitamin A and IVIG, both with limitations.

## SEC filing metadata
- accession: 0000950170-25-068543
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000095017025068543/0000950170-25-068543-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000095017025068543/ivvd-20250512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-068543
- JSON: https://secwatch.observer/filing/0000950170-25-068543.json
- Plain text: https://secwatch.observer/filing/0000950170-25-068543.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.